BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17154161)

  • 21. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.
    Ceresoli GL; Reni M; Chiesa G; Carretta A; Schipani S; Passoni P; Bolognesi A; Zannini P; Villa E
    Cancer; 2002 Aug; 95(3):605-12. PubMed ID: 12209754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of solitary brain metastasis. Resection followed by whole brain radiation therapy (WBRT) and a radiation boost to the metastatic site.
    Rades D; Raabe A; Bajrovic A; Alberti W
    Strahlenther Onkol; 2004 Mar; 180(3):144-7. PubMed ID: 14991201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature.
    Pectasides D; Aravantinos G; Fountzilas G; Kalofonos C; Efstathiou E; Karina M; Pavlidis N; Farmakis D; Economopoulos T; Dimopoulos MA
    Anticancer Res; 2005; 25(5):3553-8. PubMed ID: 16101179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
    Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
    J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?
    Carolan H; Sun AY; Bezjak A; Yi QL; Payne D; Kane G; Waldron J; Leighl N; Feld R; Burkes R; Keshavjee S; Shepherd F
    Lung Cancer; 2005 Jul; 49(1):109-15. PubMed ID: 15949596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
    Olmez I; Donahue BR; Butler JS; Huang Y; Rubin P; Xu Y
    Lung Cancer; 2010 Nov; 70(2):174-9. PubMed ID: 20207442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung.
    Guerrieri M; Wong K; Ryan G; Millward M; Quong G; Ball DL
    Lung Cancer; 2004 Oct; 46(1):107-11. PubMed ID: 15364138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
    Suh JH; Stea B; Nabid A; Kresl JJ; Fortin A; Mercier JP; Senzer N; Chang EL; Boyd AP; Cagnoni PJ; Shaw E
    J Clin Oncol; 2006 Jan; 24(1):106-14. PubMed ID: 16314619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy.
    Bischof M; Debus J; Herfarth K; Muley T; Kappes J; Storz K; Hoffmann H
    Strahlenther Onkol; 2007 Dec; 183(12):679-84. PubMed ID: 18040612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
    Rades D; Pluemer A; Veninga T; Dunst J; Schild SE
    Cancer; 2007 Oct; 110(7):1551-9. PubMed ID: 17654659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.
    Mamon HJ; Yeap BY; Jänne PA; Reblando J; Shrager S; Jaklitsch MT; Mentzer S; Lukanich JM; Sugarbaker DJ; Baldini EH; Berman S; Skarin A; Bueno R
    J Clin Oncol; 2005 Mar; 23(7):1530-7. PubMed ID: 15735128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
    Rades D; Bohlen G; Pluemer A; Veninga T; Hanssens P; Dunst J; Schild SE
    Cancer; 2007 Jun; 109(12):2515-21. PubMed ID: 17487853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
    Gow CH; Chien CR; Chang YL; Chiu YH; Kuo SH; Shih JY; Chang YC; Yu CJ; Yang CH; Yang PC
    Clin Cancer Res; 2008 Jan; 14(1):162-8. PubMed ID: 18172267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.